Citation Impact
Citing Papers
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
2008 Standout
Oncogenic Activity of Epidermal Growth Factor Receptor Kinase Mutant Alleles Is Enhanced by the T790M Drug Resistance Mutation
2007
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
2003 StandoutScience
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
2005 StandoutScience
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
2003 Standout
The short-time structural plasticity of dendritic spines is altered in a model of Rett syndrome
2011
A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia
2002
EGFR Antagonists in Cancer Treatment
2008 Standout
Ultrastructural Characterization of the Lower Motor System in a Mouse Model of Krabbe Disease
2016 Standout
Chronic Myeloproliferative Disorders
2003
Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
2009 Standout
A view on drug resistance in cancer
2019 StandoutNature
Stem cells, cancer, and cancer stem cells
2001 StandoutNature
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
2008 StandoutNature
Comparison of ATP-Binding Cassette Transporter Interactions with the Tyrosine Kinase Inhibitors Imatinib, Nilotinib, and Dasatinib
2010
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
2009 StandoutNature
Chronic myelogenous leukemia
2001
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
2002 Standout
Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia
2003
Effect of Imatinib Mesylate on Chronic Myelogenous Leukemia Hematopoietic Progenitor Cells
2003
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Foxp2 controls synaptic wiring of corticostriatal circuits and vocal communication by opposing Mef2c
2016 StandoutNobel
The biology and management of non-small cell lung cancer
2018 StandoutNature
Lung Cancer
2008 Standout
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
2013 StandoutNobel
S6K1 determines the metabolic requirements for BCR-ABL survival
2012
Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
2006 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia
2007
Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor
2010 Standout
Soft-Tissue Sarcomas in Adults
2005 Standout
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
2006 Standout
Cancer Stem Cells: Are We Missing the Target?
2004
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
2010 StandoutNature
Dynamics of chronic myeloid leukaemia
2005 Nature
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
2006
Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia
2005
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
2005 Standout
Philadelphia Chromosome–Positive Acute Myeloid Leukemia
2007
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal
2010 Nature
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
2005 Standout
Hematopoietic Stem-Cell Transplantation
2006 Standout
Diagnosis of periodontal manifestations of systemic diseases
2004
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Getting to the stem of chronic myeloid leukaemia
2008
Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program
2003
Neuroblastoma
2007 Standout
Revealing the world of RNA interference
2004 StandoutNatureNobel
Periodontal diseases
2005 Standout
Applying the discovery of the Philadelphia chromosome
2007
MEF2C haploinsufficiency caused by either microdeletion of the 5q14.3 region or mutation is responsible for severe mental retardation with stereotypic movements, epilepsy and/or cerebral malformations
2009
The Transcription Factor Mef2 Links the Drosophila Core Clock to Fas2, Neuronal Morphology, and Circadian Behavior
2013 StandoutNobel
An Overview of Real-Time Quantitative PCR: Applications to Quantify Cytokine Gene Expression
2001
PHD3 Loss in Cancer Enables Metabolic Reliance on Fatty Acid Oxidation via Deactivation of ACC2
2016 StandoutNobel
Angiogenesis as a therapeutic target
2005 StandoutNature
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
2015 Standout
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
2001 Standout
Specific Killing of Ph+Chronic Myeloid Leukemia Cells by a Lentiviral Vector-Delivered Anti-bcr/ablSmall Hairpin RNA
2003
Neuronal maturation defect in induced pluripotent stem cells from patients with Rett syndrome
2011
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
2004
Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis
2005
Imatinib (STI571)-Mediated Changes in Glucose Metabolism in Human Leukemia BCR-ABL-Positive Cells
2004
Transcription factor MEF2C influences neural stem/progenitor cell differentiation and maturation in vivo
2008
Gender Differences in UVB-Induced Skin Carcinogenesis, Inflammation, and DNA Damage
2007
The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments
2009 Standout
Modeling hepatitis C virus infection using human induced pluripotent stem cells
2012 StandoutNobel
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333-1337, 2003.
2003
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies
2004
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
2004 StandoutScience
Control of skin cancer by the circadian rhythm
2011 StandoutNobel
Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management
2014
Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum
2011 StandoutScience
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment
2003
Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR.
2001
Molecular mechanisms of resistance of leukemia to imatinib mesylate
2003
Large-scale analysis of the human and mouse transcriptomes
2002 StandoutNobel
Multiple Myeloma
2011 Standout
Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003
2007
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Chronic myeloid leukemia: current treatment options
2001
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML
2004
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
2009 StandoutScience
New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance
2006
Works of Ute Berger being referenced
Behavioral and anatomical abnormalities in Mecp2 mutant mice: A model for Rett syndrome
2007
Gender aspects in chronic myeloid leukemia: long-term results from randomized studies
2005
Chronic myeloid leukemia: a model for oncology
2005
Detection and quantification of residual disease in chronic myelogenous leukemia
2000
Interferon α in the treatment of polycythemia vera
2000
Response and resistance in 300 patients with BCR‐ABL–positive leukemias treated with imatinib in a single center
2005
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
2002
Current trends in the management of chronic myelogenous leukemia
2000
Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR
1999
Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission
2000
Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases
2002